» Articles » PMID: 2594786

N-terminal Galanin-(1-16) Fragment is an Agonist at the Hippocampal Galanin Receptor

Overview
Specialty Science
Date 1989 Dec 1
PMID 2594786
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The galanin N-terminal fragment [galanin-(1-16)] has been prepared by solid-phase synthesis and by enzymic cleavage of galanin by endoproteinase Asp-N. This peptide fragment displaced 125I-labeled galanin in receptor autoradiography experiments on rat forebrain and spinal cord and in equilibrium binding experiments from high-affinity binding sites in the ventral hippocampus with an IC50 of approximately 3 nM. In tissue slices of the same brain area, galanin-(1-16), similarly to galanin, inhibited the muscarinic agonist-stimulated breakdown of inositol phospholipids. Upon intracerebroventricular administration, galanin-(1-16) (10 micrograms/15 microliters) also inhibited the scopolamine (0.3 mg/kg, s.c.)-evoked release of acetylcholine, as studied in vivo by microdialysis. Substitution of [L-Trp2] for [D-Trp2] resulted in a 500-fold loss in affinity as compared with galanin-(1-16). It is concluded that, in the ventral hippocampus, the N-terminal galanin fragment [galanin-(1-16)] is recognized by the galanin receptors controlling acetylcholine release and muscarinic agonist-stimulated inositol phospholipid breakdown as a high-affinity agonist and that amino acid residue [Trp2] plays an important role in the receptor-ligand interactions.

Citing Articles

Galanin in an Agnathan: Precursor Identification and Localisation of Expression in the Brain of the Sea Lamprey .

Sobrido-Camean D, Yanez-Guerra L, Lamanna F, Conde-Fernandez C, Kaessmann H, Elphick M Front Neuroanat. 2019; 13:83.

PMID: 31572131 PMC: 6753867. DOI: 10.3389/fnana.2019.00083.


Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness.

Hokfelt T, Barde S, Xu Z, Kuteeva E, Ruegg J, Le Maitre E Front Neural Circuits. 2019; 12:106.

PMID: 30627087 PMC: 6309708. DOI: 10.3389/fncir.2018.00106.


A Review of Single-Nucleotide Polymorphisms in Orexigenic Neuropeptides Targeting G Protein-Coupled Receptors.

Ericson M, Haskell-Luevano C ACS Chem Neurosci. 2018; 9(6):1235-1246.

PMID: 29714060 PMC: 6042215. DOI: 10.1021/acschemneuro.8b00151.


Positive allosteric modulators to peptide GPCRs: a promising class of drugs.

Bartfai T, Wang M Acta Pharmacol Sin. 2013; 34(7):880-5.

PMID: 23624758 PMC: 4002610. DOI: 10.1038/aps.2013.20.


Neuropeptide receptor positive allosteric modulation in epilepsy: galanin modulation revealed.

Hoyer D Proc Natl Acad Sci U S A. 2010; 107(34):14943-4.

PMID: 20713719 PMC: 2930528. DOI: 10.1073/pnas.1010365107.


References
1.
Amiranoff B, Lorinet A, Yanaihara N, Laburthe M . Structural requirement for galanin action in the pancreatic beta cell line Rin m 5F. Eur J Pharmacol. 1989; 163(1):205-7. DOI: 10.1016/0014-2999(89)90421-4. View

2.
Fisone G, Langel U, Carlquist M, Bergman T, Consolo S, Hokfelt T . Galanin receptor and its ligands in the rat hippocampus. Eur J Biochem. 1989; 181(1):269-76. DOI: 10.1111/j.1432-1033.1989.tb14721.x. View

3.
Melander T, Kohler C, Nilsson S, Hokfelt T, Brodin E, Theodorsson E . Autoradiographic quantitation and anatomical mapping of 125I-galanin binding sites in the rat central nervous system. J Chem Neuroanat. 1988; 1(4):213-33. View

4.
Young 3rd W, Kuhar M . A new method for receptor autoradiography: [3H]opioid receptors in rat brain. Brain Res. 1979; 179(2):255-70. DOI: 10.1016/0006-8993(79)90442-6. View

5.
Fisher S, Boast C, Agranoff B . The muscarinic stimulation of phospholipid labeling in hippocampus is independent of its cholinergic input. Brain Res. 1980; 189(1):284-8. DOI: 10.1016/0006-8993(80)90030-x. View